Aurora Cannabis (TSE:ACB) Reaches New 52-Week Low at $0.76

Shares of Aurora Cannabis Inc. (TSE:ACB – Get Rating) reached a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.76 and last traded at C$0.76, with a volume of 624043 shares trading hands. The stock had previously closed at C$0.78.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ACB. Jefferies Financial Group cut their price target on Aurora Cannabis from C$1.80 to C$1.31 in a research note on Tuesday, February 28th. Stifel Nicolaus cut their price objective on shares of Aurora Cannabis from C$1.45 to C$1.20 in a report on Monday, February 13th. Canaccord Genuity Group cut their price objective on shares of Aurora Cannabis from C$2.00 to C$1.50 in a report on Friday, February 10th. Finally, CIBC cut their target price on Aurora Cannabis from C$2.25 to C$1.75 and set a “neutral” rating on the stock in a research note on Monday, February 13th. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Aurora Cannabis has an average rating of “Hold” and an average target price of C$2.22.

Aurora Cannabis Trading Down 3.8 %

The stock has a market cap of C$255.74 million, a PE ratio of -0.10 and a beta of 3.00. The firm has a 50-day simple moving average of C$0.90 and a 200-day simple moving average of C$1.27. The company has a quick ratio of 2.48, a current ratio of 4.08 and a debt-to-equity ratio of 38.00.

Aurora Cannabis (TSE:ACB – Get Rating) last announced its quarterly earnings results on Thursday, February 9th. The company reported C($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.09) by C($0.10). The firm had revenue of C$69.17 million for the quarter, compared to analysts’ expectations of C$57.00 million. Equities analysts forecast that Aurora Cannabis Inc. will post -0.22 earnings per share for the current year.

Aurora Cannabis Company Profile

(Get Rating)

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, Caribbeans, South America, and Israel; and distribution and sale of hemp-derived cannabidiol (CBD) products in the United States (U.S.) market.